AT ISSUE: Promega Corp.'s sale of Taq polymerase for PCR has riled Hoffmann-La Roche.
At stake is not only the validity of a lucrative patent, but also the question of whether academic scientists must worry about whether someone might own patent rights to enzymes or processes they wish to use in their research. Patent experts interpret recent court decisions as being broadly favorable to Promega, but the case is far from settled. Caught in the middle...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?